IP Library Granted Patent US 11,753,619
Granted Patent B2
US 11,753,619 · App. 16/482,497 · Granted Sep 12, 2023

Engineered cells and methods of use

Inventors: Peng Wu (San Diego, CA); Jie Li (San Diego, CA); Yiran Zhou (San Diego, CA); Mingkuan Chen (San Diego, CA)
Assignee: The Scripps Research Institute
C12N5/0006A61K47/549A61K47/6849A61K47/6855A61K47/6901A61P35/00C07K16/2827C07K16/2854C07K16/32C12N5/0636C12N5/0639C12N5/0646C12N5/10C12N9/1051C07K2317/55C07K2317/622
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,753,619
App. No.
16/482,497
Granted
Sep 12, 2023
Kind
B2
Abstract

Provided herein are engineered cells, comprising: a chemical or biological moiety covalently bound to a cell surface glycan, wherein the chemical or biological moiety is selected from the group consisting of small molecule, polynucleotide, polypeptide, and antibody. Also provided are compositions comprising these engineered cells and methods of making and using the same.

Claims (8)

1. An engineered cell, comprising:

an antibody covalently bound to a N-acetylglucosamine (GlcNAc) cell surface glycan through a GDP-fucose via a α-1,3 linkage.

2. The engineered cell of claim 1 , wherein the engineered cell is a T-cell or a natural killer (NK) cell, or a Dendritic Cell (DC).

3. The engineered cell of claim 1 , wherein the antibody is a single chain variable fragment (scFv), fragment antigen binding (Fab) fragment, or a full length antibody.

4. The engineered cell of claim 1 , wherein the antibody is an immunoglobulin G (IgG) antibody.

5. The engineered cell of claim 4 , wherein the IgG is a full length IgG.

6. The engineered cell of claim 1 , wherein the engineered cell is a chimeric antigen receptor (CAR)-T cell.

7. The engineered cell of claim 6 , wherein the CAR-T cell comprises a genetically modified T-cell with the cell surface GlcNAc covalently bound to a GDP-Fucose bearing a new motif.

Assignments (3)
CONFIRMATORY LICENSE Recorded Aug 11, 2023
From: SCRIPPS RESEARCH INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 064572/0265 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2019
From: WU, PENG; LI, JIE; ZHOU, YIRAN; CHEN, MINGKUAN
To: THE SCRIPPS RESEARCH INSTITUTE
Reel/Frame 049919/0051 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2019
From: WU, PENG; LI, JIE; CHEN, MINGKUAN
To: THE SCRIPPS RESEARCH INSTITUTE
Reel/Frame 049920/0538 →
Continuity (3)
Provisional Application 62578721 · Oct 30, 2017
Provisional Application 62453922 · Feb 2, 2017
Related Publication 20200010795A1 · Jan 9, 2020